Treatment of lithium-induced diabetes insipidus with amiloride

• Published in: Pharmacotherapy Vol. 23; no. 4; p. 546
• Main Authors: Finch, Christopher K, Kelley, Kristi W, Williams, Raela B
• Format: Journal Article
• Language: English
• Published: United States 01.04.2003
• Subjects: Amiloride - therapeutic use; Diabetes Insipidus - blood; Diabetes Insipidus - chemically induced; Diabetes Insipidus - drug therapy; Female; Humans; Lithium Carbonate - adverse effects; Lithium Carbonate - blood; Middle Aged
• DOI: 10.1592/phco.23.4.546.32121
• ISSN: 0277-0008

A 63-year-old African-American woman was admitted to the hospital with urosepsis and altered mental status. She had a history of schizophrenia and was treated with olanzapine 5 mg/day and lithium carbonate 300 mg 3 times/day. During her hospital stay, her sodium level and serum osmolality increased and her urine osmolality decreased, whereas her lithium levels remained within normal limits. Based on these findings, the patient was diagnosed with diabetes insipidus secondary to lithium therapy and was treated successfully with amiloride. Clinicians have been aware of lithium toxicity for many years and traditionally have administered thiazide diuretics for lithium-induced polyuria and nephrogenic diabetes insipidus. Recently, amiloride, a potassium-sparing diuretic, has been reported as a successful treatment for nephrogenic diabetes insipidus.